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Human diseaseEditorial text
Germline mutations arise anew during meiosis in every
generation. Such spontaneously occurring genetic altera-
tions are termed de novo mutations and serve to describe
those heritable mutations that neither parent possessed or
transmitted. Thus, de novo mutations denote mutations
that arose in the gametes of the parents as distinct from
post-zygotic somatic mutations that arise during embryonic
development. Studies of de novo mutations in the human
genome have been very challenging owing to past
technological limitations. However, the advent of high-
through put next-generation sequencing (NGS) technolo-
gies has ushered in a new era in the study of de novo muta-
tions. Whole-genome sequencing (WGS) and whole-exome
sequencing (WES) can now be performed on parent-
offspring trios to identify de novo point mutations in the
entire genome or within protein-coding regions, respect-
ively [1-3]. Although genome-wide de novo copy number
variants (CNVs) were previously studied using microar-
rays [4-7], the study of de novo point mutations or single
nucleotide variants (SNVs) required the advent of large-
scale sequencing, which was not feasible using Sanger
sequencing [1-3]. As with inherited mutations, de novo
mutations range in size from point mutations and small
indels of multiple bases to much larger CNVs and struc-
tural rearrangements [8]. In this article, we focus on de
novo point mutations/SNVs and their implications for
our understanding of the etiology of common complex
diseases as well as rare Mendelian diseases.
The availability of NGS has allowed first estimations of
the human genome mutation rate as well as a glimpse of* Correspondence: cheeseng.ku@ki.se; cooperDN@cardiff.ac.uk
1Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
Nobels väg 12B, Stockholm SE-171 77, Sweden
3Institute of Medical Genetics, Cardiff University, Heath Park, Cardiff, Cardiff
CF14 4XN, UK
Full list of author information is available at the end of the article
© 2012 Ku et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the orthe spatial distribution of de novo point mutations in the
human genome and their association with heritable dis-
eases [1-3,9-13]. Recent studies have estimated the per-
generation mutation rate in humans as approximately
10−8. For example, sequencing the complete genomes
from two parent-offspring trios (from the HapMap CEU
and YRI, to >22-fold mapped depth) identified a total of
49 and 35 germline de novo point mutations in the two
trios, respectively [2]. Similarly, an average de novo muta-
tion rate of 1.20 × 10−8 per nucleotide per generation
was also reported by sequencing the entire genomes of
78 Icelandic parent-offspring trios [3]. Interestingly, the
diversity in the mutation rate of SNVs was found to be
strongly influenced by the age of the father when the
child was conceived (the impact of paternal age corre-
sponds to about two mutations per year). These findings
have highlighted the likely importance of the father's age
for the risk of those diseases which appear to be strongly
affected by de novo mutations, e.g., schizophrenia and
autism (see below) [3]. However, the mutation rate is
critically dependent upon the type of mutation being
considered, as the CNV mutation rate is somewhat
higher than the single base-pair substitution mutation
rate [14].
Owing to technical limitations, the contribution of de
novo point mutations to human genetic diseases (both
common complex disease and rare Mendelian disorder)
has remained largely unexplored. De novo point muta-
tions are nevertheless likely to have severe biological or
phenotypic consequences when they impact functionally
important nucleotides in the genome (for example, non-
sense mutations or missense mutations in evolutionarily
conserved regions). However, only a relatively small pro-
portion of the de novo point mutations occurring at each
meiosis will alter functionally important nucleotides
[1-3]. Although de novo CNVs have been shown, using
whole-genome genotyping arrays, to be associated withThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Ku et al. Human Genomics 2012, 6:27 Page 2 of 4
http://www.humgenomics.com/content/6/1/27several common neurodevelopmental diseases such as
schizophrenia and autism [4-7], it was not until very re-
cently that de novo point mutations were also implicated
in the etiology of schizophrenia, autism, and mental re-
tardation through the WES of affected trios [9-12,15-17].
In similar vein, de novo point mutations have also been
found to be responsible for sporadic cases of various rare
dominant Mendelian disorders such as Kabuki syn-
drome, Schinzel-Giedion syndrome, and Bohring-Opitz
syndrome [18-20]. These Mendelian disorders are also
characterized by multiple neurodevelopmental defects;
thus, for example, Bohring-Opitz syndrome is a clinically
recognizable syndrome characterized by severe intellec-
tual disability, distinctive facial features, and multiple
congenital malformations [20].
It has been postulated that the occurrence of de novo
mutations might explain why diseases characterized by dra-
matically reduced fecundity such as mental retardation and
schizophrenia nevertheless remain frequent in the popula-
tion. If this were indeed to be the case, the de novo muta-
tions occurring in sporadic cases of these diseases would
serve to replenish the number of highly penetrant disease
mutations in every generation despite the continual nega-
tive selection. Indeed, de novo CNVs are a known cause of
schizophrenia, autism, and mental retardation [21,22]. In
addition, de novo point mutations have also been identified
in schizophrenia through the WES of affected case-parent
trios. In the exomes of 53 sporadic schizophrenia cases
(with no history of the disease in a first- or second-degree
relative), 22 unaffected controls and their parents were
sequenced which led to the identification of a total of 34 de
novo point mutations/SNVs and 4 de novo indels in the
affected trios. However, it is noteworthy that some de novo
SNVs (four non-synonymous and three synonymous) were
also identified in the control subjects. This suggests that
identifying the pathogenic and/or deleterious de novo
mutations from a non-disease-associated mutational back-
ground may be a tricky task [11]. In a parallel develop-
ment, de novo mutations were also found to be enriched
in autism spectrum disorder (ASD)/autism [15-17]. A
large WES study of 238 families from a comprehensively
phenotyped ASD cohort comprising pedigrees with two
unaffected parents and an affected proband (and in 200
families, an unaffected sibling) found that highly disrup-
tive (nonsense and splice-site) de novo point mutations
in brain-expressed genes were associated with ASDs and
that these mutations carried large effects. De novo point
mutations have also been identified in individuals with
unexplained mental retardation [9]. These findings pro-
vide further support for the likely importance of de
novo mutations in the etiology of these complex neu-
rodevelopmental disorders.
De novo heterozygous point mutations are also
believed to be a common cause of sporadic cases ofthose rare Mendelian diseases that are characterized by
multiple congenital malformations or anomalies, devel-
opmental delay, and mental retardation or intellectual
disability such as Schinzel-Giedion syndrome and
Bohring-Opitz syndrome, the genetic basis of which had
previously remained elusive [19,20]. These disease-
causing de novo mutations were undetected by linkage
analysis because they were not transmitted between the
generations. Although the conventional gene-centric
approach of limited Sanger sequencing is capable of
identifying de novo point mutations, this method can-
not realistically be scaled up to encompass the entire
genome, exome, or even all genes on a chromosomal
arm. Further, it is a hypothesis-driven approach whereby
the selection of candidate genes is highly dependent
upon an a priori hypothesis which is in turn constrained
by our still limited knowledge of the biological pathways
that characterize the diseases in question. By contrast,
WES constitutes a powerful and robust tool which can
be used to unravel de novo point mutations by screening
the entire coding region of the genome (i.e., all the
exons) of the affected parent-offspring trios. The first
success in identifying novel de novo mutations for rare
diseases came with the identification of the MLL2 gene
underlying Kabuki syndrome, even although this study
did not adopt a trio design [18]. Instead, the exomes
of unrelated probands from different families were
sequenced in order to identify the causal genes, and in
families where parental DNA was available, the muta-
tions were confirmed to be de novo in some of them [18].
However, similar success was also obtained in studies
that applied WES to affected trios for various rare dis-
eases. Thus, de novo mutations in the EZH2 gene under-
lying Weaver syndrome [23] and in the ACTB and
ACTG1 genes underlying Baraitser-Winter syndrome
were identified by means of WES of trios [24].
The advantage of applying WES to parent-case trios is
that it narrows down the list of potential candidate dis-
ease mutations very considerably because of the limited
number of de novo point mutations to be expected
within protein-coding sequences. This is of course espe-
cially useful for disorders in which de novo mutations
are strongly suspected, e.g., Baraitser-Winter syndrome
(a rare but now well-defined developmental disorder).
No familial recurrence or consanguinity has ever been
observed in families affected with this syndrome; hence,
the genetic basis of Baraitser-Winter syndrome was al-
ways likely to be due to the occurrence of de novo point
mutations (as no pathogenic CNVs had been detected
using microarrays) [24]. WES would be sufficient to
identify the mutations underlying most rare Mendelian
disorders as long as the causative mutations reside
within the coding regions. In contrast to WGS, WES is
more cost-effective and analytically less challenging.
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proach, for example, to a family quartet affected by a
sporadic case of severe epileptic encephalopathy. WGS
of the family, containing an affected proband and her
unaffected parents and sibling, revealed a de novo
heterozygous missense mutation in SCN8A [25].
Although numerous de novo point mutations have
now been identified which are responsible for rare disor-
ders, it remains unclear what constitutes evidence for
causality. It is both difficult and challenging to establish
the causative role of newly identified mutations, even for
de novo events. Co-segregation of the putative causal
mutation with a disease phenotype in large pedigrees
might provide strong genetic evidence of causality, but
this would not be applicable in the case of de novo
mutations which are, by definition, not transmitted
through the generations. Therefore, for a newly identi-
fied putative pathological mutation which appears to
have occurred de novo, further screening of additional
cases is invariably required. Detection of recurrent mu-
tation (or identical mutations) or different mutations in
the same gene in additional cases and their absence in
healthy individuals constitutes strong evidence of causal-
ity. However, it might be quite difficult, in the context of
extremely rare disorders, to find additional cases with
which to validate the newly identified de novo mutation.
Although challenging, further validation in additional
samples has generally been successful in recent WES
studies of rare disorders. Most notably, after the discov-
ery of de novo point mutations in ACTG1 and ACTB by
WES of three parent-case trios with Baraitser-Winter
syndrome, the study used Sanger sequencing to screen
the coding sequence of both genes in 15 additional
affected individuals and was successful in detecting
pathogenic mutations in one or other of these genes in
all subjects studied [24]. These mutations were then
shown to have occurred de novo in all 11 subjects from
whom parental DNA was available. Moreover, further
validation in normal controls showed that none of the
mutations identified in Baraitser-Winter syndrome were
present in several large control datasets [24]. As an alter-
native, molecular functional studies to confirm the func-
tional significance of newly identified de novo mutations
could be considered confirmatory if and when the
mutated gene had a clear role in conferring a well-
defined molecular pathology.
The studies of de novo mutations that have been per-
formed so far have adopted the WES approach. However,
the current shortcoming of WES lies in its necessary
focus on coding regions. Hence, the clinicobiological im-
portance of de novo mutations in non-coding regions
remains unclear. Although very challenging, WGS even-
tually promises to permit the comprehensive analysis
of de novo mutations (and other inherited variants) inthe human genome in collections of case-parent trios
affected by various heritable diseases. Since a consider-
able number of inherited mutations for various diseases
have now been found in non-coding regions [26], it is
reasonable to suppose that this could also pertain in the
context of de novo mutations within non-coding regions.
This in turn supports the likely efficacy of a strategy of
adopting WGS to ascertain the full impact of de novo
mutations in human genetic disease and to study the
molecular characteristics of such lesions. The collection
of a large number of such trios would be important in
this context. The discovery to date of de novo mutations
underlying common complex diseases as well as rare
Mendelian disorders is likely to represent only the tip of
the iceberg; more discoveries would be anticipated in
the near future.
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